Za-AV · Determination of physiologically relevant RNA substrate(s) and design of small-molecule inhibitors for Zα domains as potential intervention strategies for viral infections and autoimmunity
Horizon 2020 — Marie Skłodowska-Curie Actions
- Duration
- 2018-04-01 → 2020-03-31
- EU contribution
- €160,636
- Participants
- 1
- Scheme
- MSCA-IF
Lines connect the coordinator with its partners.
Results in brief
Determination of physiologically relevant RNA substrate(s) and design of small-molecule inhibitors for Zα domains as potential intervention strategies for viral infections and autoimmunity
The problems being addressed by the actions pertained to finding out the substrate specificity of Z-alpha domains using RNA-seq analysis and the subsequent biophysical characterisation of the protein and its cognate substrate/s.This issue is important to society because viral infections cause a lot of economic and social hardships. Viruses are recognized by host immune system that activates interferon response pathway to bring about viral clearance. However, the magnitude of the response is modulated in order to prevent infliction of self injury. Recognition of Z-conformation of nucleic acids by protein domains called Z-alpha play an important role in this balance between self and non-self discrimination. Insights from this work will provide critical insights into design of antiviral strategies. The overall objective of the actions was to determine the substrate nucleic acids recognized by Z-alpha domain and attempts at designing small-molecule binders for these protein domains. The current project, after an year since its inception, has been successful in standardizing RNA-seq experiments. The RNA-seq pipeline was standardized in E.coli and the results were analyzed. Contrary to previous reports, analysis of the resultant RNA-seq data showed that Zα domain of ADAR1 preferentially binds to 5S rRNA from E. coli. Subsequently, the analysis was carried on polyA and non poly A enriched RNA fractions from A549 cells mammalian cell lines pulled down employing the wild-type and nucleic acid binding deficient mutant of Zαβ domains from ZBP1. The analysis of the pulldown data provides us with a list of preferential RNA substrates pulled down by the wild-type protein vis-à-vis the mutant variant. We had hypothesized that, since the Zα domain is a part of the multidomain protein ADAR1 that is involved in A to I editing, it is highly likely that inosine containing sequences having a propensity for adopting Z conformation might be a recognizable motif for Zα domain to bind to specific nucleic acid substrates. Further, haplotype-based variant analysis shows a slight enrichment of A2G mutations (indicative of A to I editing) in the RNA pool pulled-down by wild-type vis-à-vis mutant. However, this conclusion needs further experiments to validate. Furthermore, in support of the hypothesis that inosine containing oligonucleotides form the preferential substrate for Zα domains, we have demonstrated the binding of Zαβ domains from ZBP1 to oligonucleotides enriched in TI and CI containing repeats using electrophoretic mobility gel shift assays. Additionally, the study has also attempted to qualitatively model the isothermal titration calorimetry data of Zα domain binding to the oligonucleotides T(CG)3 and T(CG)6 constrained by the assumption that the protein domain can bind only to the Z-conformation. Further experiments are needed to model the data quantitatively and to eliminate the possibility of an induced fit to Z-conformation rather than a lock and key picture. Further, as part of effort to discover novel small-molecules binding to Zα domain, we had projected to carry out virtual ligand screening and high-throughput experimental screening. Before experimental screening, successful virtual ligand screening (VLS) was carried out using hybrid next-generation methodologies combining the principles of both structure-based and ligand-based screening approaches. FINDSITEcomb, a fold-based approach, and PoLi, a pocket-based approach, were employed to predict small-molecule binders for the Zα domain of ADAR1 and Zαβ domain of ZBP1. This project was pivotal for my training in both scientific and transferable skills, for expanding my network, for giving me exposure into project management and for contributing holistically to advancing my overall scientific temperament. I could not only pursue my science but attended training workshops in science communication, use of social media for effective science outreach and RNA-seq analysis. The results obtained thus far, as part of the Marie Skłodowska-Curie Actions (MSCA), have contributed towards providing preliminary insights into the substrate specificity preferences of Zα domains. This is a significant first step in understanding how Zα domain´s recognition of specific RNA molecules regulate important processes such as antiviral/proviral responses and discrimination of self from non-self.
Data: CORDIS, © European Union
Project objective
DNA/RNA molecules adopting the Z-conformation have been known to possess immunogenic properties. However, their biological role and importance has been a topic of debate for many years. The discovery of Z-DNA/RNA binding domains (Zα domains) in varied proteins that are involved in the innate immune response, such as the interferon induced form of the RNA editing enzyme ADAR1 (p150), Z-DNA binding protein 1 (ZBP1), the fish kinase PKZ and the pox-virus inhibitor of interferon response E3L, indicates important roles of Z-DNA/RNA in immunity and self/non-self-discrimination. Such Zα domain-containing proteins recognize Z-DNA/RNA in a conformation-specific manner. Recent studies have implicated these domains in viral recognition. Given these important emerging roles for the Zα domains, it is pivotal to understand the physiologically-relevant nucleic acid substrate for them. In this proposal, we propose to deduce the physiologically relevant substrates for Zα domains from ADAR1 p150 and ZBP1 employing next-generation RNA-seq methodologies. Knowledge on the biochemical and structural aspects of substrate specificity and substrate recognition by these domains would yield important insights into the specific roles these proteins play in the physiological context and would propel efforts at designing effective and specific small-molecule inhibitors against these proteins. Utilizing next-generation virtual ligand screening approaches and high-throughput experimental screening, efforts would be undertaken to discover potential binders/inhibitors of these domains. Small-molecule inhibitors of this domain have potential applications in anti-viral treatments especially against viruses such as influenza and human immunodeficiency virus that have huge human and economic impact as well as in the treatment of autoinflammatory disorders.
Original text from CORDIS.
Participants
- FUNDACAO CALOUSTE GULBENKIAN · LisboaCoordinatorPortugal
Links
Data: CORDIS, © European Union
